Syndrome X • Insulin Resistance Syndrome • Cardiometabolic Syndrome

Not one disease. Five findings. One upstream problem that almost nobody is checking for.

What it is

Metabolic syndrome is not a single disease. It is a cluster — a formal clinical designation given when five specific metabolic abnormalities appear together in the same person. Meeting three of the five criteria is enough for the diagnosis.

The five components are:

• Elevated fasting blood glucose — 100 mg/dL or higher, or active treatment for elevated blood glucose

• Elevated triglycerides — 150 mg/dL or higher, or active treatment for elevated triglycerides

• Low HDL cholesterol — below 40 mg/dL in men, below 50 mg/dL in women, or active treatment for low HDL

• High blood pressure — 130/85 mmHg or higher, or active treatment for hypertension

• Excess abdominal circumference — greater than 40 inches in men, greater than 35 inches in women by ATP III criteria

Three out of five. That is the threshold. Metabolic syndrome affects an estimated one in three American adults. It is one of the strongest predictors of cardiovascular disease and Type 2 diabetes risk available in clinical practice.

The reason these five findings cluster together is that they share underlying mechanisms — primarily involving insulin resistance and altered handling of glucose and fat at the cellular level. They are not five separate problems requiring five separate solutions. They are five expressions of the same disrupted metabolic machinery.

What it is not

Metabolic syndrome is not:

• A single disease with a single cause — it is a pattern of findings with shared mechanisms

• Exclusively caused by lifestyle — genetics drive significant predisposition, and the cluster can appear across a wide range of body types and activity levels

• Simply fixed by weight loss — weight loss can improve the picture meaningfully, but the underlying metabolic tendency is not erased by losing weight

• Something that only affects people who look a particular way — visceral fat — the fat surrounding internal organs — is metabolically active and dangerous at levels that may not be obvious externally

• A complete explanation by itself — metabolic syndrome is a description of what is present, not a full accounting of why

The five findings — and what they share

Each of the five components of metabolic syndrome connects back to disrupted insulin signaling and altered fat metabolism.

Elevated fasting blood glucose reflects cells that are not responding normally to insulin — the early metabolic signature of insulin resistance, often present years before a Type 2 diabetes diagnosis.

Elevated triglycerides reflect how the liver handles excess carbohydrate and disrupted fat metabolism. When insulin signaling is impaired, the liver converts excess substrate into triglycerides and releases them into the bloodstream. Elevated triglycerides are one of the earliest and most sensitive markers of metabolic disruption.

Low HDL travels with elevated triglycerides as a metabolic pair — when triglycerides go up, HDL tends to go down. Both reflect the same underlying dysregulation of lipid metabolism.

High blood pressure connects to insulin resistance through several mechanisms including sodium retention, sympathetic nervous system activation, and endothelial dysfunction driven by chronic metabolic stress.

Excess abdominal circumference reflects visceral fat — fat stored around internal organs rather than subcutaneously. Visceral fat is metabolically active, producing inflammatory signals and contributing directly to insulin resistance. It is a cause and a consequence simultaneously.

The finding that most often hides something else — elevated triglycerides

Of the five components of metabolic syndrome, elevated triglycerides deserve the most careful second look.

Elevated triglycerides in the context of metabolic syndrome are almost universally attributed to carbohydrate intake, dietary fat, insulin resistance, or some combination. That attribution is frequently correct.

But there is an upstream cause that produces elevated triglycerides, NAFLD, and reactive hypoglycemia simultaneously — through a completely different mechanism — and the standard metabolic syndrome workup is not designed to find it.

HFI Triad note: Elevated triglycerides, NAFLD, and reactive hypoglycemia can each appear as standalone findings — but when they cluster together, especially alongside a history of aversion to sweet foods or abdominal symptoms after fructose-containing meals, hereditary fructose intolerance is worth considering. HFI is an Aldolase B enzyme deficiency that causes the liver to accumulate fructose-1-phosphate. That accumulation drives fat production, triglyceride elevation, and fatty liver through a mechanism that has nothing to do with insulin resistance — but produces a picture that looks nearly identical on standard labwork. The standard metabolic syndrome workup does not test for it. See the HFI page in the Metabolic & Genetic section of the Medical Library.

If the triglycerides won't move the way they should on standard interventions — dietary change, medication, carbohydrate reduction — and especially if reactive hypoglycemia and fatty liver are also in the picture, that upstream question is worth asking explicitly.

The NAFLD connection

Non-alcoholic fatty liver disease is not one of the five formal criteria for metabolic syndrome, but it is so commonly present alongside the cluster that many researchers consider it an unofficial sixth component.

The liver sits at the center of the metabolic syndrome picture. It processes glucose, produces triglycerides, regulates fat storage, and mediates the hormonal signals that connect food intake to energy use. When insulin resistance disrupts those processes, the liver accumulates fat. NAFLD is the visible result.

NAFLD ranges from simple steatosis — fat accumulation without significant inflammation — to non-alcoholic steatohepatitis (NASH), which involves active inflammation and carries risk of progression to cirrhosis and liver failure.

The standard workup for NAFLD in the context of metabolic syndrome does not include testing for hereditary fructose intolerance. NAFLD caused by HFI looks identical on ultrasound, CT, and MRI to NAFLD caused by insulin resistance. The liver does not label its fat by cause. If NAFLD is present alongside elevated triglycerides and reactive hypoglycemia — especially in someone whose metabolic picture does not respond as expected to standard management — the HFI differential is worth raising with your physician.

History

The formal concept of metabolic syndrome as a clinical entity was developed in the latter decades of the twentieth century, with Gerald Reaven's 1988 Banting Lecture — delivered to the American Diabetes Association — representing a landmark moment. Reaven described the cluster of insulin resistance, elevated triglycerides, low HDL, and hypertension as a unified syndrome he called Syndrome X. Elevated blood glucose and abdominal obesity were incorporated into the formal criteria as the definition evolved through the 1990s and 2000s.

The ATP III criteria — published by the National Cholesterol Education Program in 2001 — provided the specific numeric thresholds that most clinicians still use. The International Diabetes Federation published alternative criteria in 2005 with different waist circumference cutoffs by ethnicity, reflecting that the metabolic risk associated with visceral fat varies across populations.

The epidemic expansion of metabolic syndrome diagnoses in the latter decades of the twentieth century tracks closely with shifts in the food supply — particularly the widespread deployment of high-fructose corn syrup beginning in the mid-1970s, the dramatic increase in processed food consumption, and the reduction in dietary fat replaced by carbohydrate in response to the low-fat dietary guidelines of the 1980s. The research on causation in this area is genuinely complex and contested. The timing correlation is documented and hard to dismiss.

What you can do about it

Metabolic syndrome does not have a single treatment because it is not a single disease. Management addresses the components — individually and collectively — through dietary change, physical activity, and medication where indicated.

Dietary approaches with documented benefit: Low carbohydrate and very low carbohydrate diets have shown consistent benefit across multiple components of metabolic syndrome simultaneously — reducing triglycerides, improving fasting glucose, and in some studies improving blood pressure and HDL. The mechanism is direct: reducing carbohydrate intake reduces the substrate load driving triglyceride production and glucose dysregulation.

Physical activity: Regular moderate physical activity improves insulin sensitivity independently of weight loss. Even modest increases in movement have documented metabolic benefit.

Component-specific medications:

• Statins and fibrates — lipid management

• Antihypertensives — blood pressure management

• Metformin — glucose management, sometimes used in pre-diabetes

• GLP-1 receptor agonists — benefit across multiple components simultaneously

What to watch for: Management of one component in isolation — treating the triglycerides without addressing the glucose, or treating the blood pressure without addressing the underlying insulin resistance — addresses the symptom without the mechanism. The cluster tends to respond best to interventions that address the shared underlying disruption rather than each finding separately.

Asking for the right test

Metabolic syndrome is diagnosed from standard labwork, but a fuller picture requires going beyond the minimum panel.

The five criteria — standard tests:

• Fasting blood glucose

• Fasting lipid panel — triglycerides and HDL specifically

• Blood pressure measurement

• Waist circumference

For a fuller metabolic picture:

• Fasting insulin level — not routinely ordered but reveals insulin resistance before glucose rises into the diabetic range. The combination of normal fasting glucose with elevated fasting insulin is an early signal of compensated insulin resistance.

• HbA1c — average blood glucose over three months

• Full liver enzyme panel — ALT, AST, GGT — to assess NAFLD

• Uric acid — elevated in insulin resistance and metabolic syndrome, associated with gout risk

• hsCRP — high-sensitivity C-reactive protein — marker of the chronic low-grade inflammation that accompanies metabolic syndrome

• Complete thyroid panel — TSH, Free T3, Free T4, TPO antibodies — thyroid dysfunction affects every component of metabolic syndrome and is frequently missed with TSH alone

What the standard workup does not include: If elevated triglycerides, NAFLD, and reactive hypoglycemia are all present — especially alongside any history of food aversion to sweets or fruit — ask your physician about hereditary fructose intolerance as a differential. The standard metabolic syndrome workup does not include Aldolase B enzyme testing or ALDOB genetic sequencing. See the HFI Testing page for the critical note on what tests are and are not safe to pursue.

Personal note

Metabolic syndrome was never named in my diagnostic journey as a formal diagnosis. But elevated triglycerides showed up in my labwork during the 28-doctor loop and nobody could explain why — including me.

I told the doctors exactly what I was eating. Gluten free. No alcohol. Meat, vegetables, occasional fruit. Very little processed, canned, or boxed food. I was not eating gluten free replacement products — no gluten free bread, no gluten free pasta, none of the packaged substitutes. I asked repeatedly, directly: why are my triglycerides skyrocketing? Nobody had an answer.

What I was offered was statins. Statins do not treat elevated triglycerides — they treat LDL cholesterol. They are not the right tool for the job. Nobody discussed diet further. The conversation began and ended with a prescription that was not indicated for the finding on the page.

I had to fight to get a prescription for fenofibrate — which is actually indicated for elevated triglycerides. That fight should not have been necessary. The correct medication for a documented finding should not require a patient to do their own research and push back against a physician who had already moved on.

What was actually driving my triglycerides was HFI — a liver that could not process fructose, converting it to fat and releasing it as triglycerides. The occasional fruit. That was enough. A liver without functional Aldolase B cannot safely process fructose in any amount. It does not matter how clean the rest of the diet is. The fructose goes in, the liver cannot clear it, and out come the triglycerides. The standard metabolic workup was not looking for that. Nobody was looking for that.

If your triglycerides are elevated and you have already done everything right — clean diet, no alcohol, no processed food — and the numbers still will not move, that is not a character failing and it is not a mystery without an answer. It may be an upstream cause the standard workup has not tested for yet. The HFI page is worth reading carefully before you accept that the standard workup has found everything there is to find.

I'm not a doctor. I'm not telling you to change your medication.

Sources

• Reaven GM (1988) — Role of insulin resistance in human disease. Banting Lecture. Diabetes. PMID: 3056758 — PubMed

• National Cholesterol Education Program (NCEP) ATP III Guidelines (2001) — National Heart, Lung, and Blood Institute — nhlbi.nih.gov

• Alberti KG, et al. (2009) — Harmonizing the metabolic syndrome: a joint interim statement. Circulation. PMID: 19805654 — PubMed

• Eckel RH, Grundy SM, Zimmet PZ (2005) — The metabolic syndrome. Lancet. PMID: 15823380 — PubMed

• Bray GA, Nielsen SJ, Popkin BM (2004) — Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. American Journal of Clinical Nutrition. PMID: 15051594 — PubMed

• Chalasani N, et al. (2018) — The diagnosis and management of nonalcoholic fatty liver disease. Hepatology. PMID: 28714183 — PubMed

• Grundy SM, et al. (2005) — Diagnosis and management of the metabolic syndrome. Circulation. PMID: 16157765 — PubMed